Rani Therapeutics Correlations
RANI Stock | USD 1.99 0.04 2.05% |
The current 90-days correlation between Rani Therapeutics and Ikena Oncology is 0.07 (i.e., Significant diversification). The correlation of Rani Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Rani Therapeutics Correlation With Market
Modest diversification
The correlation between Rani Therapeutics Holdings and DJI is 0.23 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Rani Therapeutics Holdings and DJI in the same portfolio, assuming nothing else is changed.
Rani |
Moving together with Rani Stock
0.68 | MREO | Mereo BioPharma Group | PairCorr |
0.66 | ACRV | Acrivon Therapeutics, | PairCorr |
0.66 | AFMD | Affimed NV | PairCorr |
Moving against Rani Stock
0.52 | MNOV | MediciNova | PairCorr |
0.4 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.42 | ACIU | AC Immune | PairCorr |
0.38 | CRVS | Corvus Pharmaceuticals | PairCorr |
0.32 | AVTE | Aerovate Therapeutics | PairCorr |
0.31 | VREX | Varex Imaging Corp | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Rani Stock performing well and Rani Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Rani Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
IKNA | 0.90 | (0.11) | 0.00 | (0.09) | 0.00 | 1.80 | 5.87 | |||
ELYM | 3.87 | (0.92) | 0.00 | (2.63) | 0.00 | 6.21 | 34.87 | |||
HCWB | 13.10 | 3.70 | 0.32 | (0.97) | 8.25 | 22.00 | 352.85 | |||
RNXT | 3.47 | 0.47 | 0.09 | 1.00 | 3.88 | 7.55 | 40.06 | |||
TPST | 3.90 | (0.60) | 0.00 | (0.58) | 0.00 | 6.38 | 29.55 | |||
SCPH | 2.76 | (0.63) | 0.00 | (0.24) | 0.00 | 4.30 | 20.70 | |||
MIST | 1.85 | 0.22 | 0.13 | 0.26 | 1.57 | 7.19 | 18.66 | |||
MCRB | 4.93 | 0.32 | 0.04 | 1.12 | 5.57 | 10.84 | 28.84 | |||
LUMO | 2.35 | 0.27 | 0.03 | (0.28) | 2.95 | 5.95 | 16.25 |
Rani Therapeutics Corporate Management
Alireza Javadi | Vice Operations | Profile | |
Svai Sanford | Chief Officer | Profile | |
Mir Hashim | Chief Officer | Profile | |
Arvinder Dhalla | Vice Development | Profile | |
Bella Vazquez | Vice Resources | Profile | |
Eric Groen | General Counsel | Profile | |
Kate MBA | Chief Officer | Profile |